Overview

FDC Limited is a leading pharmaceutical company based in India, specializing in the development, manufacturing, and distribution of a wide range of healthcare products, including prescription pharmaceuticals, OTC (over-the-counter) medications, and food products. The company is known for its research and development capabilities and has a sustained focus on innovative therapies.

Therapeutic areas

API / Drug Master Files

FDC Limited holds 15 active (23 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • Arformoterol TartrateActive2026-03-31
  • SEMAGLUTIDEActive2026-03-31
  • NEPAFENACActive2024-10-04
  • BIMATOPROST USPActive2024-08-12
  • BRINZOLAMIDE USPActive2024-03-06
  • DORZOLAMIDE HYDROCHLORIDE USP (PROCESS II)Active2019-04-02
  • CINNARIZINEActive2017-09-07
  • OLOPATADINE HYDROCHLORIDE USPActive2015-06-23
  • LATANOPROST USPActive2010-05-18
  • BRIMONIDINE TARTRATE USPActive2007-09-17
  • ECONAZOLE NITRATE USPActive1993-08-09
  • TIMOLOL MALEATE USPActive1992-07-27
  • FLURBIPROFEN USPActive1989-09-07
  • ALBUTEROL SULFATE USPActive1988-12-12
  • MICONAZOLE NITRATE USPActive1988-03-04

Showing 15 of 23 Drug Master Files.

FDA compliance signals

19 FDA enforcement records linked to this company.

  • recall — Class II2025-08-06

    Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.

  • recall — Class II2025-05-14

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2025-03-26

    Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

  • recall — Class II2025-02-12

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2025-01-15

    Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

  • recall — Class II2024-12-18

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2024-11-13

    Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

  • recall — Class II2024-08-28

    Defective Container: patients are unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2024-08-21

    Defective container; yellow colored spike from cap lodged in the nozzle

  • recall — Class II2024-08-07

    Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

  • recall — Class II2024-05-15

    Defective Container: yellow-colored spike from cap lodged in the nozzle. Firm received several complaints from customers.

  • 4832018-08-16

    Complaint Investigation/Follow-Up Findings

  • 4832018-08-16

    Acceptance criteria for sampling & testing

  • 4832018-08-16

    Following/documenting laboratory controls

  • 4832018-08-16

    Procedures not in writing, fully followed

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.